###begin article-title 0
###xml 97 104 97 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">De Novo</italic>
Integrated Genomic Analysis Implicates Haploinsufficiency of Multiple Chromosome 5q31.2 Genes in De Novo Myelodysplastic Syndromes Pathogenesis
###end article-title 0
###begin p 1
Conceived and designed the experiments: TAG MJW. Performed the experiments: TAG MAP JS RAW MAW MGM YK MJW. Analyzed the data: TAG MAP JS RAW RSM JLF MAW MGM YK MJW. Contributed reagents/materials/analysis tools: TAG RSM YK MJW. Wrote the paper: TAG RAW MJW.
###end p 1
###begin p 2
###xml 654 661 654 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo</italic>
###xml 666 674 <span type="species:ncbi:9606">patients</span>
Deletions spanning chromosome 5q31.2 are among the most common recurring cytogenetic abnormalities detectable in myelodysplastic syndromes (MDS). Prior genomic studies have suggested that haploinsufficiency of multiple 5q31.2 genes may contribute to MDS pathogenesis. However, this hypothesis has never been formally tested. Therefore, we designed this study to systematically and comprehensively evaluate all 28 chromosome 5q31.2 genes and directly test whether haploinsufficiency of a single 5q31.2 gene may result from a heterozygous nucleotide mutation or microdeletion. We selected paired tumor (bone marrow) and germline (skin) DNA samples from 46 de novo MDS patients (37 without a cytogenetic 5q31.2 deletion) and performed total exonic gene resequencing (479 amplicons) and array comparative genomic hybridization (CGH). We found no somatic nucleotide changes in the 46 MDS samples, and no cytogenetically silent 5q31.2 deletions in 20/20 samples analyzed by array CGH. Twelve novel single nucleotide polymorphisms were discovered. The mRNA levels of 7 genes in the commonly deleted interval were reduced by 50% in CD34+ cells from del(5q) MDS samples, and no gene showed complete loss of expression. Taken together, these data show that small deletions and/or point mutations in individual 5q31.2 genes are not common events in MDS, and implicate haploinsufficiency of multiple genes as the relevant genetic consequence of this common deletion.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 176 183 176 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo</italic>
###xml 274 277 274 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004583-Olney1">[1]</xref>
###xml 462 469 462 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo</italic>
###xml 533 542 533 542 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1A</bold>
###xml 533 542 533 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004583-g001"><bold>Figure 1A</bold></xref>
###xml 544 547 544 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004583-LeBeau1">[2]</xref>
###xml 549 552 549 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004583-Zhao1">[3]</xref>
###xml 554 557 554 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004583-Boultwood1">[4]</xref>
###xml 559 562 559 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004583-Horrigan1">[5]</xref>
###xml 564 567 564 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004583-Lai1">[6]</xref>
###xml 678 889 678 889 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SPOCK1, KLHL3, HNRPA0, NPY6R, MYOT, PKD2L2, C5orf5, WNT8A, NME5, BRD8, KIF20A, CDC23, GFRA3, CDC25C, FAM53C, JMJD1B, REEP2, EGR1, ETF1, HSPA9, SNORD63, LOC391836, LOC729429, CTNNA1, LRRTM2, SIL1, MATR3, SNORA74A</italic>
###xml 891 894 891 894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004583-Horrigan1">[5]</xref>
###xml 896 899 896 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004583-Lai1">[6]</xref>
###xml 194 202 <span type="species:ncbi:9606">patients</span>
###xml 264 272 <span type="species:ncbi:9606">patients</span>
Heterozygous deletions spanning two distinct regions on the long arm of chromosome 5 are among the most common abnormalities detectable by conventional cytogenetic analysis in de novo (6-20% of patients) and therapy-related myelodysplastic syndromes (MDS) (40% of patients) [1]. One region spans chromosome 5q33.1 (148.6-151.1 Mb) and is associated with the 5q minus syndrome, while the other spans chromosome 5q31.2 (136.3-138.6 Mb) and is associated with both de novo MDS and acute myeloid leukemia (AML) that progresses from MDS (Figure 1A) [2], [3], [4], [5], [6]. The chromosome 5q31.2 region contains 23 annotated genes, 1 pseudogene, 3 small RNAs, and 1 predicted genes (SPOCK1, KLHL3, HNRPA0, NPY6R, MYOT, PKD2L2, C5orf5, WNT8A, NME5, BRD8, KIF20A, CDC23, GFRA3, CDC25C, FAM53C, JMJD1B, REEP2, EGR1, ETF1, HSPA9, SNORD63, LOC391836, LOC729429, CTNNA1, LRRTM2, SIL1, MATR3, SNORA74A) [5], [6].
###end p 4
###begin title 5
Chromosome 5q31.2 commonly deleted segment and array CGH plots.
###end title 5
###begin p 6
###xml 267 268 267 268 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 539 540 539 540 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 761 762 761 762 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 875 876 875 876 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1066 1067 1066 1067 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1283 1284 1283 1284 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
A. Diagram of the chromosome 5q31.2 commonly deleted segment (CDS) (136.3-138.6 megabases) and the 5q33.1 CDS associated with the 5q minus syndrome (148.6-151.1 megabases). The centromere is located at the left and the telomere to the right. B. Whole chromosome 5 log2 ratio (test/reference) plot for sample #315529 which contains del(5q) in 1/20 bone marrow cell metaphases, and has a blast count of 12%. No deletion was identified in this sample. To allow visualization of the data, each data point on the plot represents the average log2 ratio for consecutive probes in a 20,000 base pair region (median number of probes per bin = 46). The dashed lines indicate the 5q31.2 and 5q33.1 CDS locations depicted in panel A. C. (Upper panel) Whole chromosome 5 log2 ratio (test/reference) plot for sample #176267. An interstitial deletion on chromosome 5 produces a negative log2 ratio for probes located within the deletion. The deletion boundaries are indicated by the arrowheads. The deletion spans from base 86,152,517-155,672,191 (determined using segMNT). The log2 ratio deviation for the segment is consistent with the deletion of one allele. Sample #176267 contains del(5q) in 20/20 bone marrow cell metaphases (100%), and has a blast count of 7%. (Lower panel) Chromosome 5 log2 ratio (test/reference) plot for sample #176267 from 136.3-138.6 Mb, corresponding to the 5q31.2 CDS. No biallelic deletion was identified in this region.
###end p 6
###begin p 7
###xml 424 427 424 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004583-Lai1">[6]</xref>
###xml 429 432 429 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004583-Hu1">[7]</xref>
###xml 434 437 434 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004583-Liu1">[8]</xref>
###xml 439 442 439 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004583-Xie1">[9]</xref>
###xml 444 448 444 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004583-Dubourg1">[10]</xref>
###xml 792 800 <span type="species:ncbi:9606">patients</span>
Prior studies have suggested that haploinsufficiency of multiple genes is the disease mechanism associated with deletions spanning 5q31.2. However, these studies were primarily designed to identify biallelic gene mutations by analyzing the residual non-deleted 5q31.2 allele using MDS samples, AML samples, or cell lines containing a cytogenetically visible 5q31.2 deletion, and they only examined 20 of the 28 5q31.2 genes [6], [7], [8], [9], [10]. Therefore, these studies did not adequately address the possibility that haploinsufficiency of a single 5q31.2 gene could arise from a heterozygous point mutation, or small microdeletion, in a 5q31.2 gene in MDS samples lacking a cytogenetic del(5q). Finding a heterozygous nucleotide mutation or microdeletion in a single 5q31.2 gene in MDS patients without evidence of del(5q) would expedite our understanding of the pathogenesis conferred by large deletions.
###end p 7
###begin p 8
###xml 391 398 391 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo</italic>
###xml 280 288 <span type="species:ncbi:9606">patients</span>
To address the possibility that haploinsufficiency of a single 5q31.2 gene may occur in MDS, we performed a comprehensive and systematic screen using total exonic resequencing and array comparative genomic hybridization to evaluate all 28 genes in the 5q31.2 interval from 46 MDS patients (37 lacking a 5q31.2 deletion). Our data indicate that loss of one copy of chromosome 5q31.2 genes in de novo MDS occurs predominantly through large cytogenetic deletions involving many genes, not a single gene, and suggest that haploinsufficiency of multiple chromosome 5q31.2 genes is likely to be the relevant genetic consequence of this common deletion.
###end p 8
###begin title 9
Materials and Methods
###end title 9
###begin title 10
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human subjects
###end title 10
###begin p 11
###xml 46 53 46 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo</italic>
###xml 16 24 <span type="species:ncbi:9606">patients</span>
Forty-six adult patients (age >18 years) with de novo MDS (no prior malignancy, antecedent chemo- or radiotherapy) were enrolled in a study at the Siteman Cancer Center at Washington University to identify genetic factors contributing to MDS initiation and progression. Approval was obtained from the Washington University institutional review board for these studies. After obtaining written informed consent, a bone marrow sample was obtained for analysis of tumor cells, and a 6-mm punch biopsy of skin was obtained for analysis of unaffected somatic cells. Bone marrow DNA was prepared using the QIAamp DNA mini kit (Qiagen, Valencia, CA) and skin DNA was prepared using a standard phenol/chloroform extraction followed by an ethanol precipitation protocol.
###end p 11
###begin title 12
Array Comparative Genomic Hybridization
###end title 12
###begin p 13
###xml 630 634 618 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004583-Selzer1">[11]</xref>
###xml 643 644 631 632 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 739 743 727 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004583-Olshen1">[12]</xref>
###xml 778 782 766 770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004583-Cahan1">[13]</xref>
###xml 473 478 <span type="species:ncbi:9606">human</span>
Array comparative genomic hybridization (CGH) was performed using paired tumor (bone marrow) and germline (skin) genomic DNA samples (non-whole genome amplified DNA) from 20 of the 46 MDS samples that we resequenced (5/20 samples contain deletions spanning 5q31.2). These 20 samples were chosen because of sample abundance. We used a custom array CGH platform (Roche NimbleGen Systems, Inc.) containing 385,297 long oligomer (average length 51 nucleotides) probes spanning human chromosome 5 (median probe spacing approximately500 base pairs). Labeling, hybridization, washing, and scanning were performed as previously described [11]. The log2(test/reference) signals were analyzed using a circular binary segmentation algorithm (segMNT) [12] and a hidden Markov model (wuHMM) [13] to identify somatically acquired segmental DNA copy number changes. To call a copy number change, both algorithms required a segment to span a minimum of 5 consecutive probes. Full access to the primary array data and MIAME description are available at .
###end p 13
###begin title 14
Sequencing and Pyrosequencing
###end title 14
###begin p 15
###xml 69 73 69 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004583-Link1">[14]</xref>
###xml 75 79 75 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004583-Tomasson1">[15]</xref>
Sequencing and Pyrosequencing methods have been previously described [14], [15].
###end p 15
###begin title 16
Expression profiling
###end title 16
###begin p 17
###xml 161 166 <span type="species:ncbi:9606">human</span>
CD34+ cells were purified using the autoMACS system (Miltenyi). Total RNA was prepared using Trizol (Invitrogen, Carlsbad, CA), processed, and hybridized to the human Affymetrix U133plus2 array by the Siteman Cancer Center Microarray Core Facility at Washington University according to the manufacturer's instructions (see  for a complete list of protocols). In order to perform interarray comparisons, the data for each array was scaled to a target intensity of 1,500 using Affymetrix Microarray Suite software.
###end p 17
###begin title 18
Quantitative RT-PCR
###end title 18
###begin p 19
Quantitative RT-PCR was performed using total RNA extracted from CD34+ cells and the one-step Assays-on-Demand kit (Applied Biosystems). All samples were run in duplicate. Individual cDNA samples were normalized according to their levels of beta actin transcript. The comparative Ct method was used for analysis.
###end p 19
###begin title 20
Statistical analysis
###end title 20
###begin p 21
Differences in allele frequency were evaluated using Fisher's Exact test. Genotype associations were further evaluated for significance according to codominant, dominant, and overdominant genetic models by Chi-square testing. Results were corrected for multiple comparisons by the Bonferroni method. Gene expression profiling results were compared using a two-tailed t-test.
###end p 21
###begin title 22
Results
###end title 22
###begin title 23
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient characteristics
###end title 23
###begin p 24
###xml 28 35 28 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo</italic>
###xml 179 186 179 186 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 1</bold>
###xml 179 186 179 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004583-t001"><bold>Table 1</bold></xref>
###xml 529 537 529 537 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table S1</bold>
###xml 529 537 529 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004583.s001"><bold>Table S1</bold></xref>
###xml 1183 1191 1183 1191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004583.s001">Table S1</xref>
###xml 1183 1192 1183 1192 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="supplementary-material" rid="pone.0004583.s001">Table S1</xref>)</bold>
###xml 1402 1409 1402 1409 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 1</bold>
###xml 1402 1409 1402 1409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004583-t001"><bold>Table 1</bold></xref>
###xml 1414 1422 1414 1422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004583.s001">Table S1</xref>
###xml 1409 1422 1409 1422 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"> and <xref ref-type="supplementary-material" rid="pone.0004583.s001">Table S1</xref></bold>
###xml 14 22 <span type="species:ncbi:9606">patients</span>
###xml 300 308 <span type="species:ncbi:9606">patients</span>
###xml 383 391 <span type="species:ncbi:9606">patients</span>
###xml 476 484 <span type="species:ncbi:9606">patients</span>
###xml 685 693 <span type="species:ncbi:9606">patients</span>
A total of 46 patients with de novo MDS samples were chosen for study based on availability of high quality, abundant, paired bone marrow (tumor) and skin (germline) DNA samples (Table 1). Paired samples allowed us to distinguish somatic mutations from germline polymorphisms. Thirty-seven of the 46 patients did not have a chromosome 5q31.2 deletion by cytogenetics. Seven of the 9 patients with monosomy 5 or del(5q) had complex cytogenetics, and none of the 37 non-del(5q) patients had clinical evidence of 5q minus syndrome (Table S1). Cases were classified in accordance with the French-American-British (FAB) system upon diagnosis and banking of their bone marrow specimens. The patients include refractory anemia (RA), RA with ringed sideroblasts (RARS), RA with excess blasts (RAEB), RAEB in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMML), with a median International Prognostic Scoring System (IPSS) score of 1 (range 0-3), and a median blast count of 4.5% (range 0-26%). The 46 bone marrow samples were independently reviewed by a hematopathologist (JLF) and 6 cases were reclassified as acute myeloid leukemia in the World Health Organization system (Table S1). The 20 MDS samples analyzed using array CGH were chosen from the 46 MDS samples used for the resequencing studies, and had a median IPSS score of 2 (range 0-3), and a median blast count of 10% (range 1-26%) (Table 1 and Table S1).
###end p 24
###begin title 25
###xml 39 47 <span type="species:ncbi:9606">patients</span>
Clinical characteristics of the 46 MDS patients
###end title 25
###begin p 26
###xml 30 37 <span type="species:ncbi:9606">patient</span>
IPSS is not available for one patient.
###end p 26
###begin p 27
aCGH, array comparative genomic hybridization.
###end p 27
###begin title 28
Array comparative genomic hybridization
###end title 28
###begin p 29
###xml 328 336 328 336 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1</bold>
###xml 328 336 328 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004583-g001"><bold>Figure 1</bold></xref>
###xml 458 466 458 466 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1</bold>
###xml 458 466 458 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004583-g001"><bold>Figure 1</bold></xref>
###xml 800 808 800 808 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1</bold>
###xml 800 808 800 808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004583-g001"><bold>Figure 1</bold></xref>
To complement the sequence-based studies, we used array comparative genomic hybridization (CGH) to measure DNA copy number across chromosome 5 that might be missed by cytogenetics or resequencing. We detected chromosome 5 deletions using the array CGH platform in 4/5 samples that were known to have del(5q) using cytogenetics (Figure 1, and data not shown). Array CGH did not detect del(5q) in one MDS sample that had 1/20 metaphases with a del(5)(q22q34) (Figure 1). This is consistent with our analysis of AML samples in which array CGH rarely detects copy number changes if the neoplastic clone comprises <25% of bone marrow cells (judged by the percent abnormal metaphases) (Walter, et al., submitted). None of the del(5q) samples had detectable deletions on the remaining wild-type chromosome (Figure 1, and data not shown), and no cytogenetically silent microdeletions were detected in the non-del(5q) samples (data not shown).
###end p 29
###begin title 30
Nucleotide changes in 28 chromosome 5q31.2 genes
###end title 30
###begin p 31
To define the limit of detection for this DNA resequencing platform, we screened 90 MDS samples for FLT3 internal tandem duplications (ITD) using standard agarose gel electrophoresis and the Agilent LabChip. We detected 3 ITD+ samples and chose one for further analysis. We performed 6 serial dilutions of the ITD+ MDS DNA with FLT3 wild-type genomic DNA and performed PCR amplification followed by DNA sequencing of the PCR products. We could detect the FLT3 ITD when 12% of the alleles harbored the mutation, or when approximately20-25% of cells contain a heterozygous mutation (data not shown).
###end p 31
###begin p 32
###xml 169 177 169 177 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table S2</bold>
###xml 169 177 169 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004583.s002"><bold>Table S2</bold></xref>
###xml 617 624 617 624 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 2</bold>
###xml 617 624 617 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004583-t002"><bold>Table 2</bold></xref>
###xml 909 916 909 916 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 2</bold>
###xml 909 916 909 916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004583-t002"><bold>Table 2</bold></xref>
We designed and validated primers on control DNA templates for 479 amplicons covering the coding region and proximal introns of all 28 genes in the 5q31.2 interval (see Table S2 for primer sequences). We then produced 7.5 megabases of double-stranded sequence for these 28 genes in the 46 samples. To ensure comprehensive coverage of all 28 genes, we performed bidirectional sequencing of amplicons and systematically tracked whether each coding nucleotide in all 28 genes was covered once or twice in the 46 samples. On average, 94% of all coding bases were covered, and 88% of bases were sequenced on both strands (Table 2). Only 10 amplicons failed to produce adequate sequence coverage using our resequencing pipeline, and 7 of these yielded high quality sequence after primers were redesigned. One exon in NME5, CTNNA1, and LOC729429 failed for all 46 samples, accounting for their low percent coverage (Table 2).
###end p 32
###begin title 33
Coverage report, nonsynonymous and splice site nucleotide changes in de novo MDS
###end title 33
###begin p 34
Pseudogene.
###end p 34
###begin p 35
Small RNA.
###end p 35
###begin p 36
Sequence was assembled using NT_034772.
###end p 36
###begin p 37
###xml 37 44 <span type="species:ncbi:9606">patient</span>
Non-coding gene, the number of bases/patient refers to the exon region.
###end p 37
###begin p 38
###xml 37 44 <span type="species:ncbi:9606">patient</span>
Non-coding gene, the number of bases/patient refers to the whole gene.
###end p 38
###begin p 39
Reference sequence is NM_014386.2.
###end p 39
###begin p 40
Spice site SNP.
###end p 40
###begin p 41
###xml 73 77 73 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004583-Link1">[14]</xref>
###xml 348 355 348 355 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 2</bold>
###xml 348 355 348 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004583-t002"><bold>Table 2</bold></xref>
###xml 398 405 398 405 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 3</bold>
###xml 398 405 398 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004583-t003"><bold>Table 3</bold></xref>
###xml 468 474 468 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PKD2L2</italic>
A semiautomated analysis pipeline was used to identify sequence variants [14]. We restricted our analysis to nonsynonymous and splice site nucleotide changes. Variants not found in dbSNP (build 129) were resequenced in bone marrow and paired germline (skin) samples. No somatic nonsynonymous or splice site mutations were detected in the 28 genes (Table 2). However, 12 novel SNPs were identified (Table 3). Nine of these were nonsynonymous, including a stop codon in PKD2L2, and 3 occurred in non-coding genes. The minor allele frequency for these 12 SNPs was 1.1-4.7% in this MDS population.
###end p 41
###begin title 42
Novel SNPs in MDS samples
###end title 42
###begin p 43
Reference sequence is NM_014386.2.
###end p 43
###begin p 44
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient 176267 had del(5)(q13q33) in 20/20 metaphases and complete loss of heterozygosity at all SNPs, which only contributed one allele to the calculation of allele frequency, and was excluded from the calculation of genotype frequency.
###end p 44
###begin p 45
LOC391836 and SNORA74A are non-coding genes.
###end p 45
###begin p 46
NA indicates not available; A, major allele; B, minor allele; and MAF, minor allele frequency.
###end p 46
###begin title 47
SNP frequencies of the 28 chromosome 5q31.2 genes in MDS vs. race-matched controls
###end title 47
###begin p 48
###xml 494 502 494 502 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table S3</bold>
###xml 494 502 494 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004583.s003"><bold>Table S3</bold></xref>
###xml 640 646 640 646 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDC25C</italic>
###xml 713 718 713 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KLHL3</italic>
###xml 1194 1201 1194 1201 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 4</bold>
###xml 1194 1201 1194 1201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004583-t004"><bold>Table 4</bold></xref>
###xml 250 258 <span type="species:ncbi:9606">patients</span>
To assess whether germline alleles of chromosome 5q31.2 genes are associated with MDS, we compared both the allele and genotype frequencies of all known SNPs in these genes (23 nonsynonymous, 19 synonymous, and 5 from non-coding genes) in the 45 MDS patients of European ancestry from our cohort to race-matched HapMap controls. The minor allele frequency for 16/47 SNPs was less than 5% in all MDS or race-matched control samples, leaving 31 SNPs that could be analyzed with this sample size (Table S3). The minor allele frequencies of two coding SNPs were significantly over-represented in MDS cases vs. race-matched controls: rs3734166 (CDC25C R70C) (OR 1.836, 95% conf 1.030-3.272, p = 0.048), and rs2905608 (KLHL3 A157A) (OR 99.47, 95% conf 5.914-1673, p = 2.187E-10). We used pyrosequencing to genotype 190 additional samples from normal individuals of European descent (cancer free controls from Washington University, and HD100 controls) for SNPs rs3734166 and rs2905608. There was no significant difference in allele or genotype frequencies for rs3734166 (p = 0.246, p = 0.450, respectively) and rs2905608 (p = 0.214, p = 0.182, respectively) after pooling all available control data (Table 4). This study was powered to detect changes in minor allele frequencies that occurred in at least 10% of MDS cases, therefore, race-matched control samples were not genotyped for the 12 novel SNPs identified in our 46 MDS samples because they occurred at such low frequencies (1.4-4.7%).
###end p 48
###begin title 49
Allele and genotype frequencies for CDC25C(R70C) and KLHL3(A157A) SNPs in MDS and race-matched control samples
###end title 49
###begin p 50
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient 176267 had del(5)(q13q33)[20/20] and complete loss of heterozygosity at all SNPs,which only contributed one allele to the calculation of allele frequency, and was excluded from the calculation of genotype frequency.
###end p 50
###begin p 51
Bold indicates a siginificant difference at P<0.05.
###end p 51
###begin p 52
###xml 72 79 72 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004583-t003">Table 3</xref>
CFC indicates cancer free control. Other abbreviations are explained in Table 3.
###end p 52
###begin title 53
SNP loss of heterozygosity in del(5q) samples
###end title 53
###begin p 54
###xml 164 171 164 171 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 3</bold>
###xml 164 171 164 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004583-t003"><bold>Table 3</bold></xref>
###xml 184 192 184 192 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table S3</bold>
###xml 184 192 184 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004583.s003"><bold>Table S3</bold></xref>
###xml 610 618 610 618 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2</bold>
###xml 610 618 610 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004583-g002"><bold>Figure 2</bold></xref>
To assess whether preferential retention of a SNP allele occurred in the 9 monosomy 5 or del(5q) samples, we examined their sequence traces for 64 SNPs (12 SNPs in Table 3, 47 SNPs in Table S3, and 5 SNPs without race-matched control data). DNA extracted from a homogeneous population of tumor cells harboring a deletion of one copy of chromosome 5q31.2 will contain complete loss of heterozygosity for all SNPs in 5q31.2 genes that are heterozygous in the germline. Sequence traces from these bone marrow samples display only one peak at each SNP, which represents the retained SNP allele in the tumor cells (Figure 2). In contrast, DNA extracted from a heterogeneous population of cells containing both tumor cells with a del(5q), and normal cells without del(5q), produce sequence traces displaying two alleles of unequal peak heights indicating allele skewing. There were 5 SNPs that had allele skewing in 3 or more del(5q) samples, but 0/5 SNPs displayed uniform retention of the same allele (data not shown).
###end p 54
###begin title 55
5q31.2 SNP loss of heterozygosity in del(5q) samples.
###end title 55
###begin p 56
A. Sequence traces for SNP rs1059110 in tumor samples from an individual homozygous for the common allele (left), a heterozygote (middle) with a normal allele trace peak height ratio = 0.44 (i.e., no allelic imbalance), and a heterozygote (right) with an abnormal allele trace peak height ratio = 0.20 (i.e., allelic imbalance). B. Heat map of allelic imbalance for 23 SNPs from 8 del(5q) and 9 non-del(5q) MDS samples. Each column represents a sample, and each row represents a SNP. red, allelic imbalance; yellow, no evidence of allelic imbalance; grey, homozygous SNP; white, no data. Base pair location is listed in the left column. C. (left panel) Proportion of abnormal metaphases is highly correlated with allelic skewing in heterozygous SNPs. (right panel) Blast count is a poor predictor of clonality. Two samples with bone marrow myeloblast counts less than 5% are clonal, indicated by marked SNP allelic skewing. In contrast, four samples with myeloblast counts greater than or equal to 5% were non-clonal as measured by SNP allelic ratio.
###end p 56
###begin p 57
###xml 598 606 594 602 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2</bold>
###xml 598 606 594 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004583-g002"><bold>Figure 2</bold></xref>
###xml 970 978 966 974 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2</bold>
###xml 970 978 966 974 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004583-g002"><bold>Figure 2</bold></xref>
###xml 1290 1298 1286 1294 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2</bold>
###xml 1290 1298 1286 1294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004583-g002"><bold>Figure 2</bold></xref>
To address the possibility that the cellular heterogeneity present in MDS bone marrow samples could limit the use of unfractionated cells for DNA based genomic studies, we used the SNP resequencing data to determine whether we could detect clonality in MDS bone marrow samples that had less than 5 percent myeloblasts. We calculated the allele trace peak height ratio (peak height of allele A/(peak heights of alleles A+B)) for biallelic SNPs in tumor DNA samples (bone marrow). The allele peak height ratio was considered abnormal, indicating allelic imbalance, if the ratio was >/=0.7 or </=0.3 (Figure 2). The del(5q) samples had bone marrow myeloblast counts ranging from 0-17%, and an abnormal chromosome 5q31.2 in 5-100% of their bone marrow cell metaphases. The SNP allelic frequencies were highly correlated with the percent of abnormal metaphases in 8 del(5q) samples (r = 0.9385, p = 0.0006), indicating that the sequencing data accurately reflects clonality (Figure 2). In contrast, the bone marrow myeloblast count is a poor surrogate for clonality. Even at blast counts less than 5 percent, clonal cells are detected using the SNP peak height skewing data, implying that the majority of bone marrow cells may be clonal even when samples have low bone marrow myeloblast counts (Figure 2).
###end p 57
###begin title 58
Gene expression levels
###end title 58
###begin p 59
###xml 438 475 438 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HNRPA0, LOC391836, LOC729429, SNORD63</italic>
###xml 785 793 785 793 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table S4</bold>
###xml 785 793 785 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004583.s004"><bold>Table S4</bold></xref>
###xml 795 803 795 803 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3</bold>
###xml 795 803 795 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004583-g003"><bold>Figure 3</bold></xref>
###xml 891 899 891 899 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3</bold>
###xml 891 899 891 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004583-g003"><bold>Figure 3</bold></xref>
###xml 265 273 <span type="species:ncbi:9606">patients</span>
###xml 295 303 <span type="species:ncbi:9606">patients</span>
###xml 659 667 <span type="species:ncbi:9606">patients</span>
###xml 697 705 <span type="species:ncbi:9606">patients</span>
To assess whether del(5q) gene expression may be affected by mechanisms other than coding or splice site DNA mutations (i.e., mutations in non-coding DNA or epigenetic alterations), we compared the mRNA levels of 28 del(5q) genes in CD34+ purified cells from 6 MDS patients with del(5q), 20 MDS patients without del(5q), and 6 normal donors using the Affymetrix U133plus2 array. Four of the 28 genes did not have a probeset on the array (HNRPA0, LOC391836, LOC729429, SNORD63). The remaining 24 genes were rank ordered based on their median mRNA expression level (Affymetrix units) in the 6 control samples, and the average expression level of a gene for MDS patients with del(5q) (n = 6) and MDS patients without del(5q) (n = 20) was plotted relative to the level in control samples (Table S4, Figure 3). Nine of the 24 genes were called absent in 70-100% of all 32 samples (colored red in Figure 3). Consistent with haploinsufficiency, 7 genes had a significant reduction in average signal intensity in MDS samples with del(5q) compared to control samples (0.47 average fold change for MATR3, HSPA9, FAM53C, ETF1, CTNNA1, JMJD1B, and KLHL3 relative to control samples, p<0.04) and compared to MDS samples without del(5q) (0.52 average fold change relative to non-del(5q) samples, p<0.02 excluding FAM53C). No gene had mRNA levels in del(5q) samples consistently below the expected haploinsufficient level of 50%, indicating that biallelic loss of expression is not common in CD34+ samples containing del(5q). However, FAM53C and ETF1 were expressed at significantly lower levels in MDS samples without del(5q) compared to control samples (0.47 and 0.79 fold change relative to control, respectively, p</=0.03), suggesting that these genes might be altered in the absence of a cytogenetic deletion. To verify this possibility, we performed quantitative RT-PCR for FAM53C using available total RNA from CD34+ cells. Quantitative RT-PCR did not confirm the Affymetrix array results for haploinsufficiency of FAM53C (data not shown). Quantitative RT-PCR was not performed for ETF1 because only 1 of 2 probesets on the array showed reduced expression in non-del(5q) samples. In summary, of the 15 chromosome 5q31.2 genes with detectable expression by microarray, none was consistently expressed out of proportion to gene dosage.
###end p 59
###begin title 60
Gene expression levels of del(5q) genes in CD34+ cells.
###end title 60
###begin p 61
###xml 176 184 <span type="species:ncbi:9606">patients</span>
###xml 206 214 <span type="species:ncbi:9606">patients</span>
mRNA expression levels were determined for 24 del(5q) genes that had probesets on the Affymetrix U133plus2 array using total RNA extracted from CD34+ purified cells from 6 MDS patients with del(5q), 20 MDS patients without del(5q), and 6 normal control individuals. Genes were rank ordered based on the median signal intensity in control samples. The average signal intensity of MDS samples (+/- standard deviation) with or without del(5q) is plotted relative to control samples. Each tick mark on the y-axis represents 1 fold change relative to control samples. The color bar indicates the Affymetrix signal intensity values for the control samples for each gene. Genes with 70-100% of samples called absent are plotted with red lines. When multiple probesets were called present for a gene, probesets were averaged (probesets were included in the average signal if they were present in at least 4 of 6 control samples and had a median expression in controls greater than 1,500, the scaled target intensity of arrays). If all probesets were called absent for a gene, the highest median expressing probeset was used for plotting. * p<0.05 compared to control.
###end p 61
###begin title 62
Discussion
###end title 62
###begin p 63
###xml 204 211 204 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo</italic>
###xml 412 420 <span type="species:ncbi:9606">patients</span>
In this study, we determined by high-throughput resequencing and array comparative genomic hybridization (CGH) that point mutations and small deletions in chromosome 5q31.2 genes are not common events in de novo MDS. A critical aspect of this study design is that the nucleotide sequence and copy number for all of the genes in the commonly deleted segment were examined comprehensively in a large number of MDS patients without del(5q). These results therefore demonstrate that a cytogenetic deletion spanning the commonly deleted segment on chromosome 5q31.2 is the predominant genetic event leading to haploinsufficiency of multiple del(5q) genes. These results also imply that the simultaneous loss of multiple genes may be necessary for disease initiation and progression of del(5)(q31.2) associated MDS and AML.
###end p 63
###begin p 64
###xml 52 71 52 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HSPA9, CTNNA1, EGR1</italic>
###xml 209 212 209 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004583-Liu1">[8]</xref>
###xml 214 218 214 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004583-Craven1">[16]</xref>
###xml 220 224 220 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004583-Joslin1">[17]</xref>
###xml 311 316 311 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HSPA9</italic>
###xml 409 413 409 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004583-Craven1">[16]</xref>
###xml 597 603 597 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CTNNA1</italic>
###xml 689 692 689 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004583-Liu1">[8]</xref>
###xml 821 825 821 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004583-Nilsson1">[18]</xref>
###xml 879 883 879 883 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Egr1</italic>
###xml 998 1002 998 1002 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004583-Joslin1">[17]</xref>
###xml 226 235 <span type="species:ncbi:7955">Zebrafish</span>
###xml 305 310 <span type="species:ncbi:9606">human</span>
###xml 549 557 <span type="species:ncbi:9606">patients</span>
###xml 812 820 <span type="species:ncbi:9606">patients</span>
###xml 904 908 <span type="species:ncbi:10090">mice</span>
Haploinsufficiency of three 5q31.2 candidate genes (HSPA9, CTNNA1, EGR1) may contribute to disease pathogenesis, but current data suggests that these genes individually do not recapitulate all features of MDS [8], [16], [17]. Zebrafish carrying an ENU-induced heterozygous mutation in the ortholog of the human HSPA9 gene display increased apoptosis in blood cells characteristic of ineffective hematopoiesis [16]. Look and colleagues found that decreased CTNNA1 expression in CD34+CD38-CD123+Lin- cells from high risk del(5q) associated MDS or AML patients was associated with methylation of the CTNNA1 promoter, but not with point mutations of the residual allele in primary tumor cells [8]. However, others found no reduction in CTNNA1 mRNA levels below 50% in CD34+CD38-Thy1+ cells from low risk del(5q) MDS patients [18]. Most recently, Le Beau and colleagues observed that Egr1 heterozygous mutant mice have normal resting hematopoiesis, but develop myeloid diseases after treatment with ENU [17]. Collectively, the data implicate that more than one gene is likely to be involved in the pathogenesis of MDS, and support the hypothesis that haploinsufficiency of multiple 5q31.2 genes contributes to MDS initiation or progression.
###end p 64
###begin p 65
###xml 153 160 153 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo</italic>
###xml 303 311 303 311 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2</bold>
###xml 303 311 303 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004583-g002"><bold>Figure 2</bold></xref>
###xml 328 336 328 336 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1</bold>
###xml 328 336 328 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004583-g001"><bold>Figure 1</bold></xref>
###xml 576 580 576 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004583-Anderson1">[19]</xref>
###xml 582 586 582 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004583-Bigoni1">[20]</xref>
###xml 588 592 588 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004583-Jaju1">[21]</xref>
###xml 919 927 <span type="species:ncbi:9606">patients</span>
It is unlikely that a recurrent, clonally dominant, genetic event (mutation, gene silencing, or polymorphism) in these 28 genes was not detected in this de novo MDS cohort due to cellular heterogeneity or sample size. Although cellular heterogeneity in MDS bone marrow samples exists, our resequencing (Figure 2) and array CGH (Figure 1) results confirm findings from previous studies using interphase fluorescent in situ hybridization (FISH) for del(5q), which concluded that the myeloblast count often underestimates the proportion of cells that are clonally derived in MDS [19], [20], [21]. In addition, by sequencing 37 MDS samples without del(5q), there is a 0.9543 probability of detecting a 5q31.2 gene mutation if it occurs in at least 8% of MDS samples without a cytogenetic del(5q). Furthermore, we found no evidence of biallelic loss of mRNA expression of del(5q) genes in CD34+ cells harvested from our MDS patients with del(5q), and we found no SNP significantly associated with MDS or evidence of preferential retention of a residual SNP allele in MDS samples with del(5q).
###end p 65
###begin p 66
###xml 866 870 866 870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004583-Moffat1">[22]</xref>
###xml 872 876 872 876 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004583-Stegmeier1">[23]</xref>
###xml 934 939 934 939 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RPS14</italic>
###xml 1042 1046 1042 1046 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004583-Ebert1">[24]</xref>
###xml 348 353 <span type="species:ncbi:10090">mouse</span>
###xml 418 423 <span type="species:ncbi:10090">mouse</span>
###xml 592 596 <span type="species:ncbi:10090">mice</span>
###xml 1006 1014 <span type="species:ncbi:9606">patients</span>
Collectively, our data provides direct evidence supporting the hypothesis that haploinsufficiency of multiple genes in the commonly deleted segment is the most likely relevant genetic consequence of deletions spanning chromosome 5q31.2. Moving forward and testing the hypothesis of haploinsufficiency as a disease mechanism is difficult, and using mouse models is problematic. The syntenic chromosome 5q31.2 region in mouse resides on two chromosomes, making it difficult to accurately engineer a complete knockout of all the genes at once. In addition, creating individual targeted knockout mice for each candidate gene is time-consuming, cost-prohibitive, and impractical. However, it is now possible to perform comprehensive high-throughput gene knockdown screens using RNAi technology to model haploinsufficiency because lentiviral short hairpin libraries exist [22], [23]. This approach has yielded important information for the RPS14 gene located in the chromosome 5q33.1 commonly deleted segment in patients with the 5q minus syndrome [24], and this technology will expand our understanding of single gene and gene combinations that may contribute to disease initiation in MDS and AML. Ultimately, identifying the genetics events leading to MDS initiation may provide insight into targeted therapy for MDS and AML.
###end p 66
###begin title 67
Supporting Information
###end title 67
###begin p 68
(0.06 MB XLS)
###end p 68
###begin p 69
Click here for additional data file.
###end p 69
###begin p 70
(0.13 MB XLS)
###end p 70
###begin p 71
Click here for additional data file.
###end p 71
###begin p 72
(0.14 MB XLS)
###end p 72
###begin p 73
Click here for additional data file.
###end p 73
###begin p 74
(0.09 MB XLS)
###end p 74
###begin p 75
Click here for additional data file.
###end p 75
###begin p 76
###xml 151 159 151 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004583-g003">Figure 3</xref>
We thank Nadia Siddiqui for database management, Barbara Zehnbauer for assistance with the FLT3 dilution experiment, and James Ley for assistance with Figure 3.
###end p 76
###begin title 77
References
###end title 77
###begin article-title 78
Evaluation of recurring cytogenetic abnormalities in the treatment of myelodysplastic syndromes.
###end article-title 78
###begin article-title 79
Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases.
###end article-title 79
###begin article-title 80
Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5 Mb and preparation of a PAC-based physical map.
###end article-title 80
###begin article-title 81
Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome.
###end article-title 81
###begin article-title 82
Delineation of a minimal interval and identification of 9 candidates for a tumor suppressor gene in malignant myeloid disorders on 5q31.
###end article-title 82
###begin article-title 83
###xml 82 87 <span type="species:ncbi:9606">human</span>
Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q).
###end article-title 83
###begin article-title 84
A novel nuclear protein, 5qNCA (LOC51780) is a candidate for the myeloid leukemia tumor suppressor gene on chromosome 5 band q31.
###end article-title 84
###begin article-title 85
Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation.
###end article-title 85
###begin article-title 86
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human mortalin (HSPA9): a candidate for the myeloid leukemia tumor suppressor gene on 5q31.
###end article-title 86
###begin article-title 87
Evaluation of ETF1/eRF1, mapping to 5q31, as a candidate myeloid tumor suppressor gene.
###end article-title 87
###begin article-title 88
Analysis of chromosome breakpoints in neuroblastoma at sub-kilobase resolution using fine-tiling oligonucleotide array CGH.
###end article-title 88
###begin article-title 89
Circular binary segmentation for the analysis of array-based DNA copy number data.
###end article-title 89
###begin article-title 90
wuHMM: a robust algorithm to detect DNA copy number variation using long oligonucleotide microarray data.
###end article-title 90
###begin article-title 91
Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia.
###end article-title 91
###begin article-title 92
###xml 91 99 <span type="species:ncbi:9606">patients</span>
Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia.
###end article-title 92
###begin article-title 93
###xml 18 27 <span type="species:ncbi:7955">zebrafish</span>
Loss of Hspa9b in zebrafish recapitulates the ineffective hematopoiesis of the myelodysplastic syndrome.
###end article-title 93
###begin article-title 94
Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders.
###end article-title 94
###begin article-title 95
The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes.
###end article-title 95
###begin article-title 96
Fluorescence in situ hybridization for the study of cell lineage involvement in myelodysplastic syndromes with chromosome 5 anomalies.
###end article-title 96
###begin article-title 97
Multilineage involvement in the 5q- syndrome: a fluorescent in situ hybridization study on bone marrow smears.
###end article-title 97
###begin article-title 98
Combined immunophenotyping and FISH identifies the involvement of B-cells in 5q- syndrome.
###end article-title 98
###begin article-title 99
###xml 30 35 <span type="species:ncbi:9606">human</span>
###xml 40 45 <span type="species:ncbi:10090">mouse</span>
A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen.
###end article-title 99
###begin article-title 100
A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells.
###end article-title 100
###begin article-title 101
Identification of RPS14 as a 5q- syndrome gene by RNA interference screen.
###end article-title 101
###begin p 102
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 102
###begin p 103
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by National Institutes of Health Grant HL082973 (TAG, MJW), T32-HL07088 (RAW), the Center for Genome Sciences, Washington University School of Medicine (TAG, MJW), and the Aplastic Anemia & MDS International Foundation, Inc. (MJW). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 103

